Seamless Therapeutics and Eli Lilly Strike $1.12B Global Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 28 2026
0mins
Should l Buy LLY?
Source: seekingalpha
- Global Collaboration Agreement: Seamless Therapeutics has entered into a global research and licensing deal worth up to $1.12 billion with Eli Lilly, focusing on developing treatments for hearing loss based on its gene editing platform, marking a significant milestone in the biotech sector.
- Recombinase Development: Under the agreement, Seamless will concentrate on developing recombinases, enzymes designed for therapeutic editing of genes related to hearing loss, further advancing the application of gene editing technology in medicine.
- Exclusive Licensing Rights: Eli Lilly will obtain exclusive licensing rights to the recombinases programmed by Seamless and will be responsible for advancing drug development and commercialization, which will generate over $1.12 billion in revenue for Seamless, including potential development and commercial milestone payments.
- Strategic Validation: Seamless CEO Albert Seymour stated that this collaboration validates the broad disease-modifying potential of their gene editing platform, indicating significant future advancements in the treatment of hearing loss conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 954.520
Low
950.00
Averages
1192
High
1500
Current: 954.520
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Launches New Obesity Drug Foundayo
- FDA Approval: Eli Lilly's Foundayo™ (orforglipron) has received FDA approval, specifically designed for adults with obesity or overweight and related medical issues, which is expected to significantly enhance patient weight management outcomes.
- Significant Weight Loss: In the ATTAIN-1 clinical trial, participants on the highest dose lost an average of 27.3 pounds (12.4%), compared to just 2.2 pounds (0.9%) in the placebo group, demonstrating Foundayo's efficacy and market potential.
- Convenient Access: Foundayo will be available through LillyDirect®, with commercial insurance patients paying only $25 per month and self-pay patients at $149, which is expected to improve drug accessibility and meet the needs of obesity patients.
- Global Rollout Plan: Lilly plans to launch Foundayo in over 40 countries shortly after approval, aiming to enhance the quality of life for obesity patients worldwide by providing effective treatment options.
See More
Eli Lilly's New Drug Could Dominate Weight Loss Market
- Intensified Drug Competition: Eli Lilly's new drug Foundayo (orforglipron) is set to launch on April 6, positioning it to fiercely compete with Novo Nordisk's Wegovy, potentially dominating the anti-obesity drug market for the next several years.
- Significant Clinical Trial Results: In its first phase 3 trial, patients taking the 12mg dose of retatrutide lost an average of 28.7% of body weight over 68 weeks, showcasing its potential in the weight loss drug arena, surpassing Novo Nordisk's CagriSema.
- Strong Market Demand: Early indications for Novo Nordisk's oral formulation of Wegovy suggest a robust appetite for anti-obesity drugs, while orforglipron's lack of dietary restrictions may enable it to outsell Wegovy, catering to consumer preferences for convenient weight loss solutions.
- Optimistic Industry Outlook: With the dual advantages of orforglipron and retatrutide, Eli Lilly is poised to maintain a competitive edge over Novo Nordisk in the coming years, potentially reshaping the landscape of the anti-obesity drug market.
See More
Novo Nordisk and Eli Lilly Battle for Obesity Drug Market Control
- Intensifying Market Competition: Novo Nordisk's Wegovy received approval in December as the first GLP-1 weight-loss pill, while Eli Lilly's new drug orforglipron is set to launch on April 6, marking a new phase in the competition between these two companies in the rapidly growing obesity drug market.
- Medication Convenience Comparison: Orforglipron has no food or water restrictions, whereas Wegovy must be taken on an empty stomach, requiring patients to avoid food and other medications for 30 minutes prior, which could affect patient adherence and subsequently impact sales performance.
- Potential Market Opportunity: Early demand for Novo Nordisk's oral formulation of Wegovy indicates a strong appetite for non-injectable obesity drugs, and Eli Lilly's orforglipron is expected to leverage its convenience to gain market share.
- Future Competitive Landscape: Eli Lilly's retatrutide shows promising results in phase 3 trials with an average weight loss of 28.7%, while Novo Nordisk's CagriSema only achieved a 23% reduction, suggesting that Eli Lilly may maintain a competitive edge in obesity drug development, continuing to pressure Novo Nordisk in the market.
See More
Novo Nordisk and Eli Lilly Battle for Obesity Drug Market Control
- Intensifying Market Competition: Novo Nordisk's Wegovy received approval in December as the first GLP-1 weight-loss pill, while Eli Lilly's orforglipron is set to launch on April 6, marking a new phase in their rivalry in the obesity drug market.
- Product Advantage Comparison: Orforglipron's lack of food and water restrictions may make it more appealing to consumers compared to Wegovy's requirement for fasting, potentially boosting Eli Lilly's sales prospects in the market.
- Clinical Trial Data: Eli Lilly's retatrutide showed strong competitive potential in phase 3 trials, with patients losing an average of 28.7% of body weight over 68 weeks on a 12mg dose, while Novo Nordisk's CagriSema only achieved a 23% reduction, failing to meet non-inferiority standards.
- Future Development Challenges: Novo Nordisk faces long drug development timelines, with its next potential product still years away from market, allowing Eli Lilly to capitalize on orforglipron and retatrutide in the interim.
See More
Novo Nordisk Launches Wegovy Subscription Plan to Regain Market Share
- Market Share Challenge: Novo Nordisk has lost its leading position in the anti-obesity market to Eli Lilly, and despite launching new drugs and label expansions, the market penetration remains insufficient, indicating increasing competitive pressure.
- Obesity Patient Status: Approximately 40.3% of adults in the U.S. are classified as obese, but some studies suggest this figure could be as high as 70%, highlighting a significant potential market; however, only 12% of patients are currently using GLP-1 drugs, revealing a substantial opportunity.
- New Subscription Plan: Novo Nordisk has introduced a subscription plan for Wegovy lasting three, six, or twelve months, allowing patients to access discounts through telehealth platforms, aiming to enhance drug accessibility and expand market reach.
- Future Outlook: While Novo Nordisk's subscription plan may not fully reclaim market share, its pipeline progress and relatively low valuation (11x forward earnings) could present an attractive opportunity for investors, especially as growth is expected to rebound in the coming years.
See More
Novo Nordisk Launches New Subscription Model to Expand Market Reach
- Market Potential: Research indicates that approximately 70% of adults in the U.S. may be obese, yet only 12% are currently using GLP-1 drugs, highlighting significant growth opportunities in the weight loss drug market that Novo Nordisk needs to capitalize on.
- New Subscription Model: Novo Nordisk has introduced a subscription model for Wegovy prescriptions lasting three, six, or twelve months, allowing patients to access lower prescription costs through telehealth platforms, which is expected to significantly enhance drug accessibility and attract more users.
- Competitive Pressure: While Novo Nordisk's subscription model may help expand its market share, the potential for Eli Lilly to adjust its pricing poses uncertainty regarding Novo Nordisk's ability to regain its market leadership position.
- Attractive Valuation: Currently, Novo Nordisk trades at an 11x forward earnings multiple, which is below the healthcare sector average of 17.3x, suggesting that investors purchasing its shares at this level may achieve favorable returns.
See More
Eli Lilly Launches New Obesity Drug Foundayo
- FDA Approval: Eli Lilly's Foundayo™ (orforglipron) has received FDA approval, specifically designed for adults with obesity or overweight and related medical issues, which is expected to significantly enhance patient weight management outcomes.
- Significant Weight Loss: In the ATTAIN-1 clinical trial, participants on the highest dose lost an average of 27.3 pounds (12.4%), compared to just 2.2 pounds (0.9%) in the placebo group, demonstrating Foundayo's efficacy and market potential.
- Convenient Access: Foundayo will be available through LillyDirect®, with commercial insurance patients paying only $25 per month and self-pay patients at $149, which is expected to improve drug accessibility and meet the needs of obesity patients.
- Global Rollout Plan: Lilly plans to launch Foundayo in over 40 countries shortly after approval, aiming to enhance the quality of life for obesity patients worldwide by providing effective treatment options.
See More
Eli Lilly's New Drug Could Dominate Weight Loss Market
- Intensified Drug Competition: Eli Lilly's new drug Foundayo (orforglipron) is set to launch on April 6, positioning it to fiercely compete with Novo Nordisk's Wegovy, potentially dominating the anti-obesity drug market for the next several years.
- Significant Clinical Trial Results: In its first phase 3 trial, patients taking the 12mg dose of retatrutide lost an average of 28.7% of body weight over 68 weeks, showcasing its potential in the weight loss drug arena, surpassing Novo Nordisk's CagriSema.
- Strong Market Demand: Early indications for Novo Nordisk's oral formulation of Wegovy suggest a robust appetite for anti-obesity drugs, while orforglipron's lack of dietary restrictions may enable it to outsell Wegovy, catering to consumer preferences for convenient weight loss solutions.
- Optimistic Industry Outlook: With the dual advantages of orforglipron and retatrutide, Eli Lilly is poised to maintain a competitive edge over Novo Nordisk in the coming years, potentially reshaping the landscape of the anti-obesity drug market.
See More
Novo Nordisk and Eli Lilly Battle for Obesity Drug Market Control
- Intensifying Market Competition: Novo Nordisk's Wegovy received approval in December as the first GLP-1 weight-loss pill, while Eli Lilly's new drug orforglipron is set to launch on April 6, marking a new phase in the competition between these two companies in the rapidly growing obesity drug market.
- Medication Convenience Comparison: Orforglipron has no food or water restrictions, whereas Wegovy must be taken on an empty stomach, requiring patients to avoid food and other medications for 30 minutes prior, which could affect patient adherence and subsequently impact sales performance.
- Potential Market Opportunity: Early demand for Novo Nordisk's oral formulation of Wegovy indicates a strong appetite for non-injectable obesity drugs, and Eli Lilly's orforglipron is expected to leverage its convenience to gain market share.
- Future Competitive Landscape: Eli Lilly's retatrutide shows promising results in phase 3 trials with an average weight loss of 28.7%, while Novo Nordisk's CagriSema only achieved a 23% reduction, suggesting that Eli Lilly may maintain a competitive edge in obesity drug development, continuing to pressure Novo Nordisk in the market.
See More
Novo Nordisk and Eli Lilly Battle for Obesity Drug Market Control
- Intensifying Market Competition: Novo Nordisk's Wegovy received approval in December as the first GLP-1 weight-loss pill, while Eli Lilly's orforglipron is set to launch on April 6, marking a new phase in their rivalry in the obesity drug market.
- Product Advantage Comparison: Orforglipron's lack of food and water restrictions may make it more appealing to consumers compared to Wegovy's requirement for fasting, potentially boosting Eli Lilly's sales prospects in the market.
- Clinical Trial Data: Eli Lilly's retatrutide showed strong competitive potential in phase 3 trials, with patients losing an average of 28.7% of body weight over 68 weeks on a 12mg dose, while Novo Nordisk's CagriSema only achieved a 23% reduction, failing to meet non-inferiority standards.
- Future Development Challenges: Novo Nordisk faces long drug development timelines, with its next potential product still years away from market, allowing Eli Lilly to capitalize on orforglipron and retatrutide in the interim.
See More
Novo Nordisk Launches Wegovy Subscription Plan to Regain Market Share
- Market Share Challenge: Novo Nordisk has lost its leading position in the anti-obesity market to Eli Lilly, and despite launching new drugs and label expansions, the market penetration remains insufficient, indicating increasing competitive pressure.
- Obesity Patient Status: Approximately 40.3% of adults in the U.S. are classified as obese, but some studies suggest this figure could be as high as 70%, highlighting a significant potential market; however, only 12% of patients are currently using GLP-1 drugs, revealing a substantial opportunity.
- New Subscription Plan: Novo Nordisk has introduced a subscription plan for Wegovy lasting three, six, or twelve months, allowing patients to access discounts through telehealth platforms, aiming to enhance drug accessibility and expand market reach.
- Future Outlook: While Novo Nordisk's subscription plan may not fully reclaim market share, its pipeline progress and relatively low valuation (11x forward earnings) could present an attractive opportunity for investors, especially as growth is expected to rebound in the coming years.
See More
Novo Nordisk Launches New Subscription Model to Expand Market Reach
- Market Potential: Research indicates that approximately 70% of adults in the U.S. may be obese, yet only 12% are currently using GLP-1 drugs, highlighting significant growth opportunities in the weight loss drug market that Novo Nordisk needs to capitalize on.
- New Subscription Model: Novo Nordisk has introduced a subscription model for Wegovy prescriptions lasting three, six, or twelve months, allowing patients to access lower prescription costs through telehealth platforms, which is expected to significantly enhance drug accessibility and attract more users.
- Competitive Pressure: While Novo Nordisk's subscription model may help expand its market share, the potential for Eli Lilly to adjust its pricing poses uncertainty regarding Novo Nordisk's ability to regain its market leadership position.
- Attractive Valuation: Currently, Novo Nordisk trades at an 11x forward earnings multiple, which is below the healthcare sector average of 17.3x, suggesting that investors purchasing its shares at this level may achieve favorable returns.
See More
